Ananda Pharma PLC - MRX1 achieves 2 years of stability data

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION 2014/596/EU, WHICH IS PART OF UNITED KINGDOM DOMESTIC LAW PURSUANT TO THE MARKET ABUSE (AMENDMENT) (EU EXIT) REGULATIONS (SI 2019/310) ("UK MAR"). UPON THE PUBLICATION OF THIS ANNOUNCEMENT, THIS INSIDE INFORMATION (AS DEFINED IN UK MAR) IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN.

 2 June 2025

ANANDA PHARMA PLC 

("Ananda" or the "Company") 

MRX1 Achieves 2 Years of Stability Data

Ananda Pharma plc (AQSE: ANA, OTCQB: ANANF), a UK-based biopharmaceutical company developing regulatory approved cannabidiol (CBD) medicines to treat complex, chronic conditions, is pleased to announce that its lead investigational product, MRX1, has now successfully achieved twenty four months of stability data in accordance with ICH (International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use) guidelines.

To view the supporting video and ask questions please go to our Hub: https://investors.anandapharma.co.uk/link/4PKL9y

Why Stability Data is Critical

·    Demonstrates the reliability, reproducibility, and robustness of the MRX1 formulation

·    Along with the complete absence of intoxicating THC establishes the formulation as a well characterised CBD biopharmaceutical product

·    This stability data is a key differentiator between MRX1 and any unlicenced product (including a cannabis-based medicine prescribed via a cannabis clinic or available via a dispensary), any UK Food Standards Agency approved CBD product, and any CBD product produced in accordance with the Farm Bill in the USA where the reliability of product is not verified

Stability testing is part of pharmaceutical development and assesses how a drug product maintains its quality over time when exposed to various environmental conditions such as temperature, humidity, and light. Specifically, MRX1 now has 24 months of standard and accelerated stability data. Accelerated data is where MRX1 was stored under higher temperatures, normally >30⁰C, something that is particularly critical for MRX1 given its planned us in a Phase 1 trial taking place in Australia.

Regulatory authorities such as the MHRA, FDA and EMA require stability data from multiple production batches to confirm that a drug product can be manufactured consistently to the same quality standards. The company continues to add supporting data to its regulatory package, providing assurance that the manufacturing process is well-controlled and reproducible.

Ananda's CEO, Melissa Sturgess commented: "This achievement  shows the level of detail required to ensure we have a formulation that can ultimately become a regulatory approved medicine.  There are no shortcuts."

About Ananda Pharma

Ananda Pharma (AQSE: ANA) is a UK-based biopharmaceutical company developing regulatory approved, cannabidiol medicines to treat complex, chronic conditions, including epilepsy (trials funded by NHS England and NIHR), endometriosis (funded by NHS Scotland) and chemotherapy pain (funded by NIHR). The Company is led by successful entrepreneurs and is working with a team of world-class scientists, including globally respected Key Opinion Leaders at the University of Edinburgh, Great Ormond Street Hospital for Children and University College London.

To stay up to date with the latest developments at Ananda, we encourage you to follow our social media channels which are:  

·              Investor Hub: https://investors.anandapharma.co.uk/s/ea8f93

·              Instagram: https://www.instagram.com/anandapharmaplc/

·              LinkedIn:  https://www.linkedin.com/company/anandapharma

·              X: https://twitter.com/AnandaPlc

-Ends-  

For the purposes of UK MAR, the Directors of the Company accept responsibility for the contents of this announcement.